Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Lopinavir

Lopinavir

Lopinavir is a protease inhibitor medication used in the treatment of HIV infection.
It works by blocking the action of HIV protease, an enzyme essential for the replication of the virus.
PubCompare.ai can help optimize Lopinavir research by facilitating the discovery of relevant protocols from literature, pre-prints, and patents, and enabling AI-driven comparisons to identify the best protocols and products.
This can enhance the reproducibility and accuracy of Lopinavir studies, supporting more effective HIV treatment.
Leverge PubCompare.ai to streamline your Lopinavir research and enhance your findings.

Most cited protocols related to «Lopinavir»

1
Preventing HIV Transmission in Botswana
Cited 23 times
Between July 2006 and May 2008, we enrolled pregnant women with HIV-1 infection in the Mma Bana Study (meaning “mother of the baby” in Setswana) in southern Botswana. Women with CD4+ cell counts of 200 or more were randomly assigned (in permuted blocks stratified according to clinical site) to receive either 300 mg of abacavir, 300 mg of zidovudine, and 150 mg of lamivudine coformulated as Trizivir (GlaxoSmith-Kline) twice daily (the NRTI group) or 400 mg of lopinavir and 100 mg of ritonavir coformulated as Kaletra (Abbott) with 300 mg of zidovudine and 150 mg of lamivudine coformulated as Combivir (GlaxoSmithKline) twice daily (the protease-inhibitor group). Women with CD4+ cell counts of less than 200 cells per cubic millimeter or with an acquired immunodeficiency syndrome (AIDS)–defining illness received standard-of-care treatment for Botswana: 200 mg of nevirapine, 300 mg of zidovudine, and 150 mg of lamivudine twice daily (after a 2-week lead-in period of oncedaily nevirapine at a dose of 200 mg) (the observational group). Women in the randomized groups began to receive HAART between 26 and 34 weeks’ gestation and continued it through weaning or 6 months post partum (whichever occurred first), and women in the observational group began to receive HAART between 18 and 34 weeks’ gestation and continued treatment indefinitely. We report results for the primary end points at 6 months post partum.
Infants received single-dose nevirapine (6 mg) at birth and received zidovudine (4 mg per kilogram of body weight twice daily) from birth through 4 weeks. Women were counseled to exclusively breast-feed and to complete weaning 3 days before the 6-month study visit. Infants were provided free formula and foods from the time of weaning (whenever it occurred) through 12 months.
Study drugs were provided by GlaxoSmith-Kline (Trizivir and Combivir) and Abbott Pharmaceuticals (Kaletra), but these companies had no other role in the design of the study, the accrual or analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. The Botswana government provided nevirapine, Combivir, additional medications, and some laboratory testing. The Health Research Development Committee of Botswana and the Human Subjects Committee of the Harvard School of Public Health approved the study protocol and amendments. An independent data and safety monitoring board reviewed safety and efficacy data approximately every 6 months. The full study protocol including the statistical-analysis plan, is available with the full text of this article at NEJM.org. All authors vouch for the completeness and veracity of the reported data and analyses and attest that the study as reported conforms with the protocol.
Shapiro R.L., Hughes M.D., Ogwu A., Kitch D., Lockman S., Moffat C., Makhema J., Moyo S., Thior I., McIntosh K., van Widenfelt E., Leidner J., Powis K., Asmelash A., Tumbare E., Zwerski S., Sharma U., Handelsman E., Mburu K., Jayeoba O., Moko E., Souda S., Lubega E., Akhtar M., Wester C., Tuomola R., Snowden W., Martinez-Tristani M., Mazhani L, & Essex M. (2010). Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. The New England journal of medicine, 362(24), 2282-2294.
Publication 2010
abacavir Acquired Immunodeficiency Syndrome Antiretroviral Therapy, Highly Active Body Weight CD4+ Cell Counts Cells Childbirth Clinical Trials Data Monitoring Committees Combivir Cuboid Bone Food HIV-1 Homo sapiens Infant Infection Kaletra Lamivudine Lopinavir Mothers Nevirapine Pharmaceutical Preparations Pregnancy Pregnant Women Protease Inhibitors Ritonavir Trizivir Woman Zidovudine
2
Hair-Based Antiretroviral Quantification
Cited 15 times
Efavirenz, lopinavir and ritonavir reference compounds, and internal standards (IS), ritonavir-d6 and celecoxib, were obtained from Toronto Research Chemicals (Toronto, Canada). Proteinase K was purchased from Sigma™. Acetonitrile, methanol and other solvents or reagents were HPLC grade or analytical grade. Human hair samples were obtained from patients on lopinavir/ritonavir or efavirenz–based HAART in the Women’s Interagency HIV Study (WIHS). Blank human hair samples were obtained from healthy volunteers to serve as negative controls.
Huang Y., Gandhi M., Greenblatt R.M., Gee W., Lin E.T, & Messenkoff N. (2008). Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid communications in mass spectrometry : RCM, 22(21), 3401-3409.
Publication 2008
acetonitrile Antiretroviral Therapy, Highly Active Celecoxib efavirenz Endopeptidase K Hair Healthy Volunteers High-Performance Liquid Chromatographies Homo sapiens Lopinavir lopinavir-ritonavir drug combination Methanol Patients Ritonavir Solvents Woman
3
Switching to Efavirenz in HIV-infected Children
Cited 11 times
We conducted a randomized, open-label, non-inferiority trial between June 2010 and December 2013 at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa. Children were randomized to switch to efavirenz-based therapy or to continue on ritonavir-boosted lopinavir-based therapy and were followed for 48 weeks after randomization. The non-inferiority design was chosen as efavirenz was not expected to have better virologic outcomes than the standard regimen. The study was approved by the Institutional Review Boards of Columbia University and the University of the Witwatersrand. The child’s mother or legal guardian provided signed informed consent.
Children were eligible for enrollment if they had nevirapine exposure as part of PMTCT, were currently receiving ritonavir-boosted lopinavir-based therapy started <36 months of age provided for at least one year, and had an HIV RNA test <50 copies/ml. All children in the control arm of our prior trial10 (link),11 (link) still in follow-up were screened for eligibility. In addition, clinicians responsible for the care of HIV-infected children at other clinics in the area were approached about referring children meeting our eligibility criteria. Random assignments were generated by the study statistician using a permuted block design with block sizes between 8 and 12 and were concealed in opaque envelopes opened on-site at the time of randomization. Children were followed at 4, 8, 16, 24, 32, 40, and 48 weeks after randomization.
Coovadia A., Abrams E.J., Strehlau R., Shiau S., Pinillos F., Martens L., Patel F., Hunt G., Tsai W.Y, & Kuhn L. (2015). Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial. JAMA, 314(17), 1808-1817.
Publication 2015
Child efavirenz Eligibility Determination Ethics Committees, Research Legal Guardians Lopinavir lopinavir-ritonavir drug combination Mothers Nevirapine Ritonavir Testing, AIDS Therapeutics Treatment Protocols
4
Antiretroviral Efficacy and Safety in Treatment-Naive HIV-1 Patients
Cited 9 times
The PubMed/MEDLINE, Embase, and Cochrane databases were systematically searched (up to August 2013) to identify randomized controlled trials (RCTs) evaluating efficacy and/or safety of ATV/r, DRV/r, DTG, EFV, EVG/c, LPV/r, RAL, or RPV in treatment-naive HIV-1 patients. PubMed and EMBASE search terms were “HIV-1 [mesh] OR HIV infections [mesh] NOT pregnancy [mesh] AND ((dolutegravir OR GSK1349572) OR (efavirenz OR Sustiva OR Stocrin OR DMP-266) OR (raltegravir OR Isentress OR MK-0518) OR (elvitegravir OR GS-9137 OR JTK-303) OR (rilpivirine OR Edurant OR TMC 278) OR (darunavir OR Prezista OR TMC-114) OR (atazanavir OR Reyataz OR BMS-232632) OR (lopinavir OR ABT-378 OR Aluviran OR Koletra OR Kaletra) OR (Atripla OR Quad OR Stribild OR Eviplera OR Complera))”. The ClinicalTrials.gov registry, US FDA summary basis of approvals, EMA EPAR scientific discussions, and references of published systematic reviews and meta-analyses were also searched for any additional data. Abstracts of the 2013 meeting of the International AIDS Society and the Interscience Conference on Antimicrobial Agents and Chemotherapy were searched to identify recent presentations. Two phase 3 studies of DTG with data available after August 2013 were also included.
Study selection was conducted by two independent researchers who performed an initial review and selection of study titles/abstracts followed by full text review and selection. Disagreements between the reviewers were resolved by consensus. Pre-specified inclusion criteria included treatment-naive patients with HIV-1 infection; studies published in English; phase 3 or 4 RCT; patients aged ≥13 years; use of at least one of the third agents of interest; and reporting at least one of the efficacy outcomes of interest after 48 weeks of treatment. Non-randomized observational studies; single-arm studies; and studies examining different dosages of the same drug, structured treatment interruptions, maintenance treatments, or treatment switching were excluded, as were publications where outcomes specific to a treatment-naive population could not be distinguished. Studies reporting outcomes such that results could not be obtained for each treatment arm individually were also excluded. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed through all phases in the study [14] (link).
Three researchers independently abstracted data from the final selection of studies into a structured Microsoft Access database and data were reconciled for accuracy. The Effective Public Health Practice Project Quality Assessment, a quality assessment tool, was used to assess selection bias, study design, confounders, blinding, data collection methods, and withdrawals and dropouts [15] (link).
Patel D.A., Snedecor S.J., Tang W.Y., Sudharshan L., Lim J.W., Cuffe R., Pulgar S., Gilchrist K.A., Camejo R.R., Stephens J, & Nichols G. (2014). 48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis. PLoS ONE, 9(9), e105653.
Full text: Click here
Publication 2014
ABT 378 Acquired Immunodeficiency Syndrome Aftercare Atazanavir Atripla BMS 232632 Complera Conferences Darunavir DMP 266 efavirenz elvitegravir GS 9137 HIV-1 HIV Infections Infection Isentress JTK-303 Kaletra Lopinavir Microbicides MK 0518 Patients Pharmaceutical Preparations Pharmacotherapy Pregnancy Prezista Raltegravir Reyataz Rilpivirine Safety Stocrin Stribild Sustiva TMC 114 TMC 278
5
Randomized Trial of HIV Treatment in Children
Cited 9 times
Children with HIV infection were eligible for the study if they had not previously been exposed to antiretroviral agents (except for those used to prevent mother-to-child transmission of HIV), if they required treatment according to WHO criteria, and if their baseline level of plasma HIV type 1 (HIV-1) RNA was above 5000 copies per milliliter. Children (and their mothers) could not have had previous exposure to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) such as nevirapine or efavirenz (hereinafter referred to as an absence of exposure to nevirapine).
The children were stratified by age (2 to <6, 6 to <12, or 12 to 36 months) and randomly assigned in equal numbers to either nevirapine or ritonavir-boosted lopinavir, combined with zidovudine and lamivudine. Nevirapine was initially given in a dose of 4 mg per kilogram of body weight once daily for 14 days, with a dose of 7 mg per kilogram twice daily thereafter (the dose approved by the Food and Drug Administration). An amendment to the protocol (September 4, 2007) increased the nevirapine dose to 160 to 200 mg per square meter of body-surface area (once daily for 14 days, then twice daily) in line with newly instituted WHO recommendations.
Children were enrolled at one site in India and at nine sites across sub-Saharan Africa (four in South Africa and one each in Zimbabwe, Zambia, Malawi, Uganda, and Tanzania). The study was approved by the ethics review committee at each site, the Ministries of Health (where appropriate), and the institutional review board at each partner institution in the United States. Each child’s parent or legal guardian provided written informed consent. Study visits and laboratory testing were conducted as previously described.1 (link)All the authors vouch for the completeness and accuracy of the data presented. The study was conducted in accordance with the protocol, available with the full text of this article at NEJM.org. The antirectroviral drugs used in this study were donated by Abbott, Boehringer Ingelheim, and GlaxoSmithKline. Representatives of these three pharmaceutical manufacturers participated in early discussions of the trial design but not in final design decisions or in trial implementation or analyses.
Violari A., Lindsey J.C., Hughes M.D., Mujuru H.A., Barlow-Mosha L., Kamthunzi P., Chi B.H., Cotton M.F., Moultrie H., Khadse S., Schimana W., Bobat R., Purdue L., Eshleman S.H., Abrams E.J., Millar L., Petzold E., Mofenson L.M., Jean-Philippe P, & Palumbo P. (2012). Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. The New England journal of medicine, 366(25), 2380-2389.
Publication 2012
Anti-Retroviral Agents Body Surface Area Body Weight Child efavirenz Ethics Committees, Research HIV-1 HIV Infections Lamivudine Legal Guardians Lopinavir Maternal-Fetal Infection Transmission Mothers Nevirapine Nucleosides Parent Pharmaceutical Preparations Plasma Reverse Transcriptase Inhibitors Ritonavir Zidovudine

Most recents protocols related to «Lopinavir»

1
Antiretroviral Therapy in Suppressed HIV
We selected four study subjects enrolled in the Northwestern University Clinical Research Site for the MWCCS. The four men were well-suppressed patients who had received antiretroviral drugs for at least 5 years. Subject A received stavudine, tenofovir, lamivudine, and nevirapine; subject B received efavirenz, lopinavir, and tenofovir; subject C received ritonavir, amprenavir, and lamivudine/zidovudine; and subject D received indinavir and lamivudine at the sampling visits. We obtained PBMCs from cryostorage more than 5 years after starting antiretroviral therapy and undetectable plasma HIV-1 (<50 copies/ml). Laboratory procedures for clinical sample management are described elsewhere (82 (link)). The Institutional Review Board of Northwestern University approved the study (STU00022906-CR0008) with most recent approval date of 16 May 2022. All participants provided written informed consent.
Soliman S.H., Cisneros W.J., Iwanaszko M., Aoi Y., Ganesan S., Walter M., Zeidner J.M., Mishra R.K., Kim E.Y., Wolinsky S.M., Hultquist J.F, & Shilatifard A. (2023). Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. Science Advances, 9(10), eadf2468.
Publication 2023
amprenavir Clinical Laboratory Techniques efavirenz Ethics Committees, Research HIV-1 Indinavir Lamivudine lamivudine, zidovudine drug combination Lopinavir Nevirapine Patients Pharmaceutical Preparations Plasma Ritonavir Specimen Handling Stavudine Tenofovir Therapeutics
2
Antiretroviral Therapy in Murine Colitis
At 4 weeks of age, male wild type (WT; n = 17) and IL-10−/− mice (n = 40) were randomly assigned to either a placebo or combined antiretroviral therapy (cART) for 12 weeks ± 1 week. The chosen cART regimen using repurposed HIV nucleoside/nucleotide reverse transcriptase inhibitors and protease inhibitors had been evaluated for activity in antagonizing MMTV in vitro and demonstrated antiviral activity in vivo corresponding with improvement of inflammatory disease in prior studies [21 (link)]. Animals were fed ad libitum with cART added to the drinking water, freshly prepared every second day for 12 weeks, to achieve a daily dose of 1 mg emtricitabine and 1.5 mg tenofovir disoproxil fumarate nucleoside/nucleotide reverse transcriptase inhibitors as well as 4 mg lopinavir boosted with 1 mg ritonavir protease inhibitors, as described previously [21 (link)]. Control treatment group mice received ground placebo tablets in their drinking water. Water consumption was monitored daily and mouse weights measured weekly.
Armstrong H., Rahbari M., Park H., Sharon D., Thiesen A., Hotte N., Sun N., Syed H., Abofayed H., Wang W., Madsen K., Wine E, & Mason A. (2023). Mouse mammary tumor virus is implicated in severity of colitis and dysbiosis in the IL-10−/− mouse model of inflammatory bowel disease. Microbiome, 11, 39.
Full text: Click here
Publication 2023
Animals Antiviral Agents Emtricitabine HIV Reverse Transcriptase IL10 protein, human Inflammation inhibitors Lopinavir Males Mouse mammary tumor virus Mus Nucleosides Nucleotides Placebos Protease Inhibitors Psychotherapy, Multiple Reverse Transcriptase Inhibitors Ritonavir SERPINA1 protein, human Tenofovir Disoproxil Fumarate Treatment Protocols Water Consumption
3
SARS-CoV-2 Interfering Substances Evaluation
A total of 25 interfering substances were purchased through the national reference material resource platform, including purified mucin, α-interferon, oseltamivir, peramivir, lopinavir, fluticasone, etc. Inactivated viral cultures of the SARS-CoV-2 original strain were diluted as positive samples with lysates containing a negative nasal swab matrix (interfering substances such as drugs and antibiotics may interfere with the test results). In this study, 25 interfering substances were prepared in different concentrations provided in the Table 1, and then added to the above positive samples.
Finally, the mixed samples were tested on the dipstick strip, and each sample was tested at least three times in duplicate.
Li J., Shi J., Zhou Z., Yang B., Cao J., Cao Z., Zeng Q., Hu Z, & Yang X. (2023). Development of an Antigen Detection Kit Capable of Discriminating the Omicron Mutants of SARS-CoV-2. Vaccines, 11(2), 303.
Full text: Click here
Publication 2023
Antibiotics, Antitubercular Fluticasone Interferon-alpha Lopinavir Mucins Nose Oseltamivir peramivir Pharmaceutical Preparations SARS-CoV-2 Strains
4
Metabolic Modulators for Cell Line Screening
Ponatinib, Bazedoxifene and Lopinavir were purchased from Selleck Chemicals (Houston, TX, USA). 2-Deoxy-D-glucose (2-DG), O-benzyl-L-Serine (BenSer), 6-diazo-5-oxo-norleucine (DON), bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES), Telaglenastat (CB-839), epigallocatechin gallate (EGCG), 2-allyl-1-hydroxy-9,10-anthraquinone (R162), L-buthionine-sulfoximine (BSO), L-glutamine, glutamic acid and dimethyl 2-oxoglutarate were all purchased from Sigma (Sigma-Aldrich, St. Louis, MO, USA). The caspase-3 fluorescence dye was from Sartorius (Sartorius AG, Göttingen, Germany). Human IL-11Rα and negative control siRNA were from Thermofisher Scientific (Scoresby, VIC, Australia).
Stuart S.F., Bezawork-Geleta A., Areeb Z., Gomez J., Tsui V., Zulkifli A., Paradiso L., Jones J., Nguyen H.P., Putoczki T.L., Licciardi P.V., Kannourakis G., Morokoff A.P., Achuthan A.A, & Luwor R.B. (2023). The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis. International Journal of Molecular Sciences, 24(4), 3356.
Full text: Click here
Publication 2023
9,10-anthraquinone bazedoxifene CASP3 protein, human CB-839 Diazooxonorleucine dimethyl-2-oxoglutarate epigallocatechin gallate Fluorescent Dyes Glucose Glutamic Acid Glutamine Homo sapiens Lopinavir oxytocin, 1-desamino-(O-Et-Tyr)(2)- ponatinib RNA, Small Interfering Serine Sulfides
5
Transporter Inhibition Assay Protocol
OATP1B1, OATP1B3, NTCP and vector control cell lines were cultured and subsequent transporter assays conducted as described above using the same transporter‐specific probe substrates and incubation times. For OATP1B1, the probe substrate was [3H]‐estradiol 17β‐D‐glucuronide (0.02 μM) incubated for 2 min, with rifamycin SV (100 μM) as positive control inhibitor. For IC50 determinations, the only difference to the method performed above was that the 15‐min pre‐incubation step contained a range of six concentrations of protease inhibitor drug, and subsequent incubations were conducted with the same six concentration levels of drug rather than with a single concentration. All four protease inhibitor drugs were studied against OATP1B1 using pre‐incubation/incubation concentrations of either 0.1, 0.3, 1, 3, 10 and 30 μM for atazanavir and darunavir, or 0.03, 0.1, 0.3, 1, 3 and 10 μM for lopinavir and ritonavir. Based upon the results determined from the inhibition screen, only atazanavir and lopinavir were studied against OATP1B3 or NTCP using concentrations of 0.1, 0.3, 1, 3, 10 and 30 μM and 0.03, 0.1, 0.3, 1, 3 and 10 μM, or 0.3, 1, 3, 10, 30 and 50 μM and 0.1, 0.3, 1, 3, 10 and 20 μM, respectively.
For each drug, determined percentage (vehicle) control transport activity was plotted against nominal inhibitor concentration and fitted using SigmaPlot 12.5 (Systat Software Inc., Chicago, IL; four parameter logistic equation) to determine the concentration that produces half‐maximal inhibition of probe substrate transport (IC50; equivalent to Ki assuming competitive inhibition as probe substrate concentration in the assay is at least 10‐times lower than its Km).
Elsby R., Coghlan H., Edgerton J., Hodgson D., Outteridge S, & Atkinson H. (2023). Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3. Pharmacology Research & Perspectives, 11(2), e01060.
Full text: Click here
Publication 2023
Atazanavir Biological Assay Cell Lines Darunavir Estradiol Glucuronides Lopinavir Membrane Transport Proteins Pharmaceutical Preparations Protease Inhibitors Psychological Inhibition rifamycin SV Ritonavir

Top products related to «Lopinavir»

1
Lopinavir by Merck Group
Sourced in United States, Germany
Lopinavir is a laboratory product manufactured by Merck Group. It is a protease inhibitor used in research applications.
2
Lopinavir by Selleck Chemicals
Sourced in United States
Lopinavir is a type of laboratory equipment used for scientific research and analysis. It functions as a protease inhibitor, which is a class of compounds that block the activity of certain enzymes. The core function of Lopinavir is to inhibit the activity of proteases, which are enzymes involved in various biological processes.
3
Ritonavir by Merck Group
Sourced in United States, Germany
Ritonavir is a pharmaceutical product developed by Merck Group. It is a protease inhibitor used in the treatment of HIV infection. The core function of Ritonavir is to prevent the human immunodeficiency virus (HIV) from multiplying in the body by inhibiting the activity of the HIV protease enzyme.
4
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
5
Atazanavir by Bristol-Myers Squibb
Sourced in United States
Atazanavir is a protease inhibitor drug used in the treatment of HIV-1 infection. It is a prescription medication developed and manufactured by Bristol-Myers Squibb.
6
Lopinavir by LGC
Sourced in Canada
Lopinavir is a pharmaceutical product used as a core component in various laboratory equipment. It serves as a key ingredient in the formulation and development of laboratory-grade solutions and reagents. The primary function of Lopinavir is to provide a reliable and consistent chemical compound for use in various analytical and research applications.
7
Ritonavir by Abbott
Sourced in United States
Ritonavir is a laboratory diagnostic equipment used for the detection and quantification of the antiviral drug Ritonavir. It is designed to provide accurate and reliable measurements of Ritonavir levels in various biological samples, supporting clinical research and therapeutic monitoring.
8
Amprenavir by Merck Group
Sourced in Macao, Germany
Amprenavir is a protease inhibitor used in the treatment of HIV infection. It is a laboratory reagent used in research and development. The core function of Amprenavir is to inhibit the activity of the HIV protease enzyme, which is essential for the replication of the virus.
9
Ritonavir by Selleck Chemicals
Sourced in Germany
Ritonavir is a chemical compound used as a laboratory tool. It serves as a protease inhibitor, a class of molecules that can inhibit the activity of certain enzymes. The core function of Ritonavir is to act as a research tool for scientific investigations.
10
Darunavir by Merck Group
Sourced in Italy
Darunavir is a laboratory equipment product manufactured by Merck Group. It is a protease inhibitor used in the analysis and research of pharmaceutical compounds.

More about "Lopinavir"

Lopinavir is a critical antiviral medication used in the treatment of HIV/AIDS.
As a protease inhibitor, it works by blocking the action of the HIV protease enzyme, which is essential for the replication of the virus.
This helps to suppress viral load and prevent the progression of the disease.
Related compounds like Ritonavir, Atazanavir, Amprenavir, and Darunavir are also protease inhibitors used in HIV/AIDS therapy.
These drugs work in a similar fashion to Lopinavir, disrupting the viral life cycle and slowing the spread of infection.
The solvent DMSO is sometimes used in Lopinavir formulations to enhance bioavailability and absorption.
Researchers can leverage tools like PubCompar.ai to streamline their Lopinavir studies - the platform can help identify the best protocols and products from the literature, preprints, and patents, boosting the reproducibility and accuracy of their work.
This supports the development of more effective HIV treatments for patients.
By understanding the mechanisms of action, related compounds, and optimization tools for Lopinavir research, scientists can advance the field of HIV/AIDS therapeutics and improve patient outcomes.
A holistic, data-driven approach is key to driving progress in this critical area of medicine.